logo
Plus   Neg
Share
Email

Rathbone Brothers FY Pre-tax Profit Rises

Investment and wealth management services provider, Rathbone Brothers Plc (RAT.L) reported that its profit before tax for the year ended 31 December 2020 rose to 43.8 million pounds from last year's 39.7 million pounds, reflecting a number of expected items, primarily in relation to the acquisition of Speirs & Jeffrey.

But profit attributable to equity holders of the company for the year declined to 26.65 million pounds or 47.6 pence per share from 26.92 million or 48.7 pence per share in the prior year.

On an underlying basis, earnings per share were 133.3 pence in 2020, compared to 132.8 pence in 2019.

Net interest income for the year dropped to 8.42 million pounds from 16.41 million pounds in the prior year. Net fee and commission income was 353.75 million pounds down from 328.97 million pounds in the previous year.

Funds under management and administration (FUMA) grew by 8.5% to reach 54.7 billion pounds at 31 December 2020, reflecting both strong investment performance and growth. Underlying profit before tax increased by 4.3% to 92.5 million pounds.

The company noted that the outlook for 2021 is uncertain and it can expects continuing volatility.

The company announced a final 2020 dividend of 47 pence per share, which brings the total dividend to 72 pence per share, an increase of 2.9% over 2019. The dividend will be paid on 11 May 2021 to shareholders on the register on 23 April 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Johnson & Johnson's (JNJ) Covid-19 vaccine is expected to be back on track as early as this weekend as a decision is expected after the advisory panel meeting of the U.S. Centers for Disease Control and Prevention (CDC) slated on April 23, according to Dr. Anthony Fauci, the chief medical adviser to President Joe Biden. MK-4482, the experimental antiviral drug for COVID-19, showed promise to prevent and treat SARS-CoV-2 infection in hamster study, according to the scientists of National Institutes of Health or NIH. The drug significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection. MK-4482, delivered orally, is now in Phase 2 and 3 human clinical studies. Beverages giant Coca-Cola reported a 19 percent decline in profit for the second quarter from last year as a revenue growth of 5 percent and improved margins were offset by higher income taxes and interest expense. However, adjusted earnings per share and revenues topped analysts' expectations. The company also maintained its adjusted earnings and organic revenue growth outlook for fiscal 2021.
RELATED NEWS
Follow RTT